Abbott's FreeStyle Libre 2 System Aims to Improve Lives for Diabetes Patients
Abbott Laboratories has introduced its FreeStyle Libre 2 continuous glucose monitoring system, offering 14-day accuracy with optional real-time alarms.
Abbott Laboratories has launched its FreeStyle Libre 2 system, a continuous glucose monitoring (CGM) device designed to enhance the lives of individuals with diabetes. The system provides glucose readings for up to 14 days with a single sensor and features optional real-time alarms.
The device emphasizes accuracy through its Mean Absolute Relative Difference (MARD) metric, where a lower MARD indicates better performance. Abbott reports that the FreeStyle Libre 2 system achieves high accuracy, noted as being reliable from the first day of use.
Users can opt for real-time alerts that notify them of high or low glucose levels, enabling quicker responses to glycemic fluctuations. The company states that the system is designed to reduce false alarms, particularly for pediatric users, when compared to other available CGM technologies.
As diabetes prevalence continues to rise globally, the demand for advanced monitoring technologies is increasing. The FreeStyle Libre 2 system aims to address this need by offering a user-friendly and accurate solution for managing diabetes on a daily basis. Abbott suggests the device supports individuals in their diabetes management journey.